Erratum to: Health Economic Evaluation of Paricalcitol® Versus Cinacalcet + Calcitriol (Oral) in Italy
نویسندگان
چکیده
منابع مشابه
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary hyperparathyroidism, focusing on a third-party payer perspective through inclusion of medication and hospital costs, survival rates and utilities. Cost values were based on German treatment recommend...
متن کاملErratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
BACKGROUND The IMPACT SHPT [Improved Management of Intact Parathyroid Hormone (iPTH) with Paricalcitol-Centered Therapy Versus Cinacalcet Therapy with Low-Dose Vitamin D in Hemodialysis Patients with Secondary Hyperparathyroidism] study compared the effectiveness of paricalcitol and cinacalcet in the management of secondary hyperparathyroidism in haemodialysis patients but did not report the co...
متن کاملCinacalcet and vascular calcifications induced by calcitriol.
Cinacalcet and vascular calcifications induced by calcitriol Sir, We read with great interest the article by Henley et al. [1] showing that cinacalcet could not prevent vascular calcifica-tions induced by calcitriol in uraemic rats and would like to make the following comments: (1) This inefficiency might be explained by the stability of the calcium  phosphate (Ca  PO 4) product because the d...
متن کاملA randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
BACKGROUND AND OBJECTIVES Calcitriol is used to treat secondary hyperparathyroidism in patients with CKD. Paricalcitol is less calcemic and phosphatemic in preclinical studies and in some trials in dialysis patients, but head-to-head comparisons in nondialysis patients are lacking. A large meta-analysis of trials concluded that these agents did not consistently reduce parathyroid hormone (PTH) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Drug Investigation
سال: 2015
ISSN: 1173-2563,1179-1918
DOI: 10.1007/s40261-015-0284-8